PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer
| العنوان: | PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer |
|---|---|
| المؤلفون: | A. Abakar Mahamat, N. Mathé, Roger Faroux, R. Boustany, P. Soulié, L. Moreau, Isabelle Baumgaertner, R. Hervé, J. M. Phelip, D. Smith, J. M. Bons, L. Vazquez, Laurent Miglianico, Eric Francois, Rosine Guimbaud, Laurent Mineur, Louis-Marie Dourthe, A. L. Villing, S. Remy, E. Achille, N. Bonichon, Carine Plassot, I. Rabbia |
| المصدر: | PLoS ONE PLoS ONE, Vol 15, Iss 12, p e0243997 (2020) |
| بيانات النشر: | Public Library of Science, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Male, Colorectal cancer, Cancer Treatment, ECOG Performance Status, Cetuximab, medicine.disease_cause, Toxicology, Pathology and Laboratory Medicine, Metastasis, 0302 clinical medicine, Antineoplastic Agents, Immunological, Basic Cancer Research, Medicine and Health Sciences, Neoplasm Metastasis, Paronychia, Aged, 80 and over, Univariate analysis, Multidisciplinary, Hazard ratio, Smoking, Middle Aged, Tumor Resection, Primary tumor, Surgical Oncology, Treatment Outcome, 030220 oncology & carcinogenesis, Medicine, Female, KRAS, Colorectal Neoplasms, medicine.drug, Research Article, Compliance, Clinical Oncology, Adult, medicine.medical_specialty, Science, Surgical and Invasive Medical Procedures, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, Malignant Tumors, Internal medicine, medicine, Humans, neoplasms, Aged, Colorectal Cancer, Folliculitis, Toxicity, Surgical Resection, business.industry, Proportional hazards model, Cancers and Neoplasms, Biology and Life Sciences, medicine.disease, digestive system diseases, 030104 developmental biology, Clinical Medicine, business |
| الوصف: | Background Cetuximab improves progression-free survival (PFS) and overall survival (OS) in patients with KRAS wild type (wt) metastatic colorectal cancer (mCRC). Few data are available on factors impacting both efficacy and compliance to cetuximab treatment, which is, in combination with chemotherapy, a standard-of-care first-line treatment regimen for patients with KRAS wt mCRC. Patients and methods PREMIUM is a prospective, French multicenter, observational study that recruited patients with KRAS wt mCRC scheduled to receive cetuximab, with or without first-line chemotherapy, as part of routine clinical practice, between October 28, 2009 and April 5, 2012 (ClinicalTrials.gov Identifier: NCT01756625). The main endpoints were the factors impacting on efficacy and compliance to cetuximab treatment. Predefined efficacy endpoints were PFS and safety. Results A total of 493 patients were recruited by 94 physicians. Median follow-up was 12.9 months. Median progression-free survival was 11 months [9.6–12]. In univariate analyses, ECOG performance status (PS), smoking status, primary tumor location, number of metastatic organs, metastasis resectability, surgery, folliculitis, xerosis and paronychia maximum grade, and acne preventive treatment were statistically significant. In multivariate analysis (Hazard Ratios of multivariate stepwise Cox models), ECOG PS, surgery, xerosis and folliculitis were positive prognostics factors for longer PFS. Among all patients, 69 (14%) were non-compliant. In multivariate analysis, no variables were statistically significant. The safety profile of cetuximab was consistent with previous studies. Conclusions ECOG PS |
| اللغة: | English |
| تدمد: | 1932-6203 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50c7b82af2eabe85a2527740212b0928 http://europepmc.org/articles/PMC7752147 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....50c7b82af2eabe85a2527740212b0928 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19326203 |
|---|